-

Schrödinger to Present at Two Virtual Investor Conferences in July

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will present at two investor conferences in July. On Tuesday, July 20, 2021, Schrödinger will provide a corporate overview at the Evercore ISI AI x Therapeutics Day. The presentation will take place virtually at 1:30 pm. ET.

Additionally, the company will present virtually at the SVB Leerink CybeRx: Big Data, A.I. & Machine Learning in Healthcare Conference on Wednesday, July 28, 2021, at 2:00 p.m. ET.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

Schrödinger

NASDAQ:SDGR

Release Summary
Schrödinger today announced that it will present at two investor conferences in July.
Release Versions

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

More News From Schrödinger

Schrödinger Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)--Today Schrödinger announced financial results for the quarter ended June 30, 2026....

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization....

Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist....
Back to Newsroom